<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4599AA4D-F83C-40B0-A099-DCB63E3A3790"><gtr:id>4599AA4D-F83C-40B0-A099-DCB63E3A3790</gtr:id><gtr:name>Comark Instruments</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/864A9845-BA2F-4BF8-AD6D-91B724CF5991"><gtr:id>864A9845-BA2F-4BF8-AD6D-91B724CF5991</gtr:id><gtr:name>Royal Infirmary of Edinburgh</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83C1C6B9-4B22-4E1A-BBA7-3048466CAF6B"><gtr:id>83C1C6B9-4B22-4E1A-BBA7-3048466CAF6B</gtr:id><gtr:name>Sealed Envelope</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C1C85FB-77AC-4019-9363-4A2E4A909E16"><gtr:id>2C1C85FB-77AC-4019-9363-4A2E4A909E16</gtr:id><gtr:name>Cardiff &amp; Vale University Health Board</gtr:name><gtr:address><gtr:line1>Heath Park</gtr:line1><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF14 4XW</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/199BD811-2A70-46C2-A63C-2AB1DE931BBE"><gtr:id>199BD811-2A70-46C2-A63C-2AB1DE931BBE</gtr:id><gtr:name>British Transplantation Society (BTS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C705F4C9-3E9D-4C2A-90B0-49C636E962EE"><gtr:id>C705F4C9-3E9D-4C2A-90B0-49C636E962EE</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>9 Prescot Street
Aldgate</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>E1 8PR</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BA120447-B8CB-4E2B-B746-1C04FFB1DB9C"><gtr:id>BA120447-B8CB-4E2B-B746-1C04FFB1DB9C</gtr:id><gtr:name>Aesica Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0C104E4A-9974-46B0-AF00-2FED46C68ED5"><gtr:id>0C104E4A-9974-46B0-AF00-2FED46C68ED5</gtr:id><gtr:name>ESMS Global</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CD1AE87D-5F7C-4D76-A941-B5651DEC9C32"><gtr:id>CD1AE87D-5F7C-4D76-A941-B5651DEC9C32</gtr:id><gtr:name>Progeny Software inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E"><gtr:id>9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E</gtr:id><gtr:name>St George's Healthcare NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC0F0C07-730C-4D2E-B236-54B9BAB45674"><gtr:id>FC0F0C07-730C-4D2E-B236-54B9BAB45674</gtr:id><gtr:name>Fujifilm</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AF8FD2D5-1492-4026-BDAB-332A0883A75F"><gtr:id>AF8FD2D5-1492-4026-BDAB-332A0883A75F</gtr:id><gtr:name>Hammersmith Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D90B551B-BC6F-4C4D-ADD9-6C1EAD82785D"><gtr:id>D90B551B-BC6F-4C4D-ADD9-6C1EAD82785D</gtr:id><gtr:name>PCI Pharma Services</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CC884DBE-E63D-416D-8328-48CB16276834"><gtr:id>CC884DBE-E63D-416D-8328-48CB16276834</gtr:id><gtr:name>Manchester Royal Infirmary</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/88077807-2572-4B6D-8467-0822C6A212BD"><gtr:id>88077807-2572-4B6D-8467-0822C6A212BD</gtr:id><gtr:name>NHS Blood and Transplant (NHSBT)</gtr:name><gtr:address><gtr:line1>Oak House
Reeds Crescent</gtr:line1><gtr:city>Watford</gtr:city><gtr:postCode>WD24 4QN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Immunology Infection and Inflam Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4599AA4D-F83C-40B0-A099-DCB63E3A3790"><gtr:id>4599AA4D-F83C-40B0-A099-DCB63E3A3790</gtr:id><gtr:name>Comark Instruments</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/864A9845-BA2F-4BF8-AD6D-91B724CF5991"><gtr:id>864A9845-BA2F-4BF8-AD6D-91B724CF5991</gtr:id><gtr:name>Royal Infirmary of Edinburgh</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83C1C6B9-4B22-4E1A-BBA7-3048466CAF6B"><gtr:id>83C1C6B9-4B22-4E1A-BBA7-3048466CAF6B</gtr:id><gtr:name>Sealed Envelope</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C1C85FB-77AC-4019-9363-4A2E4A909E16"><gtr:id>2C1C85FB-77AC-4019-9363-4A2E4A909E16</gtr:id><gtr:name>Cardiff &amp; Vale University Health Board</gtr:name><gtr:address><gtr:line1>Heath Park</gtr:line1><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF14 4XW</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/199BD811-2A70-46C2-A63C-2AB1DE931BBE"><gtr:id>199BD811-2A70-46C2-A63C-2AB1DE931BBE</gtr:id><gtr:name>British Transplantation Society (BTS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C705F4C9-3E9D-4C2A-90B0-49C636E962EE"><gtr:id>C705F4C9-3E9D-4C2A-90B0-49C636E962EE</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>9 Prescot Street
Aldgate</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>E1 8PR</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BA120447-B8CB-4E2B-B746-1C04FFB1DB9C"><gtr:id>BA120447-B8CB-4E2B-B746-1C04FFB1DB9C</gtr:id><gtr:name>Aesica Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0C104E4A-9974-46B0-AF00-2FED46C68ED5"><gtr:id>0C104E4A-9974-46B0-AF00-2FED46C68ED5</gtr:id><gtr:name>ESMS Global</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CD1AE87D-5F7C-4D76-A941-B5651DEC9C32"><gtr:id>CD1AE87D-5F7C-4D76-A941-B5651DEC9C32</gtr:id><gtr:name>Progeny Software inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E"><gtr:id>9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E</gtr:id><gtr:name>St George's Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC0F0C07-730C-4D2E-B236-54B9BAB45674"><gtr:id>FC0F0C07-730C-4D2E-B236-54B9BAB45674</gtr:id><gtr:name>Fujifilm</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AF8FD2D5-1492-4026-BDAB-332A0883A75F"><gtr:id>AF8FD2D5-1492-4026-BDAB-332A0883A75F</gtr:id><gtr:name>Hammersmith Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D90B551B-BC6F-4C4D-ADD9-6C1EAD82785D"><gtr:id>D90B551B-BC6F-4C4D-ADD9-6C1EAD82785D</gtr:id><gtr:name>PCI Pharma Services</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CC884DBE-E63D-416D-8328-48CB16276834"><gtr:id>CC884DBE-E63D-416D-8328-48CB16276834</gtr:id><gtr:name>Manchester Royal Infirmary</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/88077807-2572-4B6D-8467-0822C6A212BD"><gtr:id>88077807-2572-4B6D-8467-0822C6A212BD</gtr:id><gtr:name>NHS Blood and Transplant (NHSBT)</gtr:name><gtr:address><gtr:line1>Oak House
Reeds Crescent</gtr:line1><gtr:city>Watford</gtr:city><gtr:postCode>WD24 4QN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/893D66CD-2721-4DA1-BC08-7050127B4B3A"><gtr:id>893D66CD-2721-4DA1-BC08-7050127B4B3A</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:otherNames>H</gtr:otherNames><gtr:surname>Sacks</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/66159703-0920-4B8C-AA02-2D00C72BA689"><gtr:id>66159703-0920-4B8C-AA02-2D00C72BA689</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Drage</gtr:surname><gtr:orcidId>0000-0003-4767-4750</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6CF032F8-E4EE-4558-A11F-90C805A52817"><gtr:id>6CF032F8-E4EE-4558-A11F-90C805A52817</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001197"><gtr:id>599E9330-6DBD-4A68-AC48-2412E49C4F1A</gtr:id><gtr:title>Development Clinical Studies - investigation into the efficacy of Mirococept in renal transplantation</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001197</gtr:grantReference><gtr:abstractText>This study is designed to improve the immediate function of a kidney transplant and also to improve its longterm outcome. A novel molecule has been designed that binds to the cell membranes of the kidney and reduces the inflammatory response after transplantation. This should result in a shorter hospital stay for the patient and a reduced need for dialysis after transplantation. There is also good evidence that improving the initial function of a kidney can improve longterm fuction, thus improving the outcome for the patient. This would also increase the number of kidneys available for transplanation to those on the waiting list.</gtr:abstractText><gtr:technicalSummary>We are seeking to define a therapeutic approach to the prevention of damage to the kidney during the period immediately after transplantation. This damage is linked to activation of the complement system which occurs through recognition of the grafted organ as ?non-self? as shown in a MRC funded programme of work. We have approached this problem firstly by engineering a recombinant form of a human complement regulatory molecule known to be present in the normal kidney and secondly by modifying this molecule so that it can be delivered to the graft by perfusion before transplantation and retained within the kidney during the period that damage is thought to occur. Preclinical and exploratory clinical studies have indicated that this approach is safe and has the potential to reduce the incidence of delayed graft function in renal transplantation. We are now seeking to conduct a larger-scale multi-centre Phase II study to investigate the clinical utility of the approach. This will at the same time validate therapeutic targets identified by animal work.</gtr:technicalSummary><gtr:fund><gtr:end>2018-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2578995</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>King's Clinical Trials Unit</gtr:department><gtr:description>KCL CTU</gtr:description><gtr:id>D8B21CE5-4EAF-4539-88B9-298FC1A719A4</gtr:id><gtr:impact>Database in place</gtr:impact><gtr:outcomeId>SaD3ue6veuv-1</gtr:outcomeId><gtr:partnerContribution>ensure the integrity of the data being collected</gtr:partnerContribution><gtr:piContribution>Provided Macros 4 trial eCRF database</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Blood and Transplant (NHSBT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DMEC (AB, KW, AC, ASF, DC, NT)</gtr:description><gtr:id>0FB936A6-A581-4A3C-8CCA-BD76DE0EFDB7</gtr:id><gtr:impact>Committee in place</gtr:impact><gtr:outcomeId>hgWJHX2aPhY-6</gtr:outcomeId><gtr:partnerContribution>Review of unblinded data and give recommendation to TSC</gtr:partnerContribution><gtr:piContribution>Data Monitoring and Ethics Committee for the EMPIRIKAL Trial: Chair and members: independent clinicians, immunologists and statisticians.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EMPIRIKAL Consortium</gtr:description><gtr:id>A9903E08-2637-40EF-9CF1-ACCE3D5C6BAE</gtr:id><gtr:impact>First investigator meeting held October 2012. Protocol modifications.</gtr:impact><gtr:outcomeId>dvHNwbVBuxo-1</gtr:outcomeId><gtr:partnerContribution>Planning of the protocol. Potential patient involvement.</gtr:partnerContribution><gtr:piContribution>We have provided the underpinning science to the clinical trial (EMPIRIKAL) of a novel membrane associated complement regulator, have formulated the clinical protocol and have secured funding with the MRC DCS to enable the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Trial Steering Committee</gtr:description><gtr:id>9021DD44-B7AC-4188-8566-0EA8E88AA0B7</gtr:id><gtr:impact>Committee in place</gtr:impact><gtr:outcomeId>KRQJ4miv4HV-3</gtr:outcomeId><gtr:partnerContribution>Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists</gtr:partnerContribution><gtr:piContribution>Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ESMS Global</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>24hr Emergency unblinding service</gtr:description><gtr:id>9597CEFA-FBD4-4061-90A3-B6C5DB0B6DC8</gtr:id><gtr:impact>Unblinding service in place</gtr:impact><gtr:outcomeId>gZbp3yMVfEw-1</gtr:outcomeId><gtr:partnerContribution>Emergency service</gtr:partnerContribution><gtr:piContribution>providing emergency unblinding service for research centres</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Surgical Sciences Oxford</gtr:department><gtr:description>DMEC (AB, KW, AC, ASF, DC, NT)</gtr:description><gtr:id>A3123480-F4DE-4054-B1E0-14046914CCE9</gtr:id><gtr:impact>Committee in place</gtr:impact><gtr:outcomeId>hgWJHX2aPhY-2</gtr:outcomeId><gtr:partnerContribution>Review of unblinded data and give recommendation to TSC</gtr:partnerContribution><gtr:piContribution>Data Monitoring and Ethics Committee for the EMPIRIKAL Trial: Chair and members: independent clinicians, immunologists and statisticians.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PCI Pharma Services</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Drug distribution, storage and packaging PCI Pharma Services</gtr:description><gtr:id>77725839-5DC4-4243-B99F-738F7924E299</gtr:id><gtr:impact>Storage and distribution plan in place</gtr:impact><gtr:outcomeId>T9Xij4bVSsg-1</gtr:outcomeId><gtr:partnerContribution>Provision of cGMP storage facilities and arrangements for distribution to trial centres</gtr:partnerContribution><gtr:piContribution>Storage and distribution for clinical supplies - Supply of information on trial design, formulation and storage requirements</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Health and Social Care Research</gtr:department><gtr:description>Trial Steering Committee</gtr:description><gtr:id>77D53E70-AC4A-434D-A0CF-BC4EC398BCF0</gtr:id><gtr:impact>Committee in place</gtr:impact><gtr:outcomeId>KRQJ4miv4HV-4</gtr:outcomeId><gtr:partnerContribution>Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists</gtr:partnerContribution><gtr:piContribution>Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>Trial Steering Committee</gtr:description><gtr:id>D450C366-7DB9-4CFA-973B-545912DA4DF8</gtr:id><gtr:impact>Committee in place</gtr:impact><gtr:outcomeId>KRQJ4miv4HV-2</gtr:outcomeId><gtr:partnerContribution>Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists</gtr:partnerContribution><gtr:piContribution>Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Sir William Dunn School of Pathology</gtr:department><gtr:description>Cytectin structural studies</gtr:description><gtr:id>6C210EB8-363C-4B5C-B749-062AD1269BA4</gtr:id><gtr:impact>Publication May 2013 Cell Reports
Cell Rep. 2013 May 30;3(5):1369-77. doi: 10.1016/j.celrep.2013.04.029. Epub 2013 May 9.
Structural basis for recognition of the pore-forming toxin intermedilysin by human complement receptor CD59.
Johnson S, Brooks NJ, Smith RA, Lea SM, Bubeck D.
PMID: 23665225 [PubMed - in process] PMCID: PMC3675674</gtr:impact><gtr:outcomeId>KMCnMHZ3NY5-1</gtr:outcomeId><gtr:partnerContribution>Oxford University provided data on its structural interaction with membranes.</gtr:partnerContribution><gtr:piContribution>Provided Cytectin</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Infirmary of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Empirikal Patient Recruiting Centres</gtr:description><gtr:id>69893B9C-B428-4543-BCC1-35319280C1E1</gtr:id><gtr:impact>recruitment to Cohort 1 of the study completed (n=80).</gtr:impact><gtr:outcomeId>jDPDP6NXrx5-6</gtr:outcomeId><gtr:partnerContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:partnerContribution><gtr:piContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Coventry and Warwickshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Empirikal Patient Recruiting Centres</gtr:description><gtr:id>69FD944F-546E-4796-89F5-F66D39B3595A</gtr:id><gtr:impact>recruitment to Cohort 1 of the study completed (n=80).</gtr:impact><gtr:outcomeId>jDPDP6NXrx5-9</gtr:outcomeId><gtr:partnerContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:partnerContribution><gtr:piContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>British Transplantation Society (BTS)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Trials Network</gtr:department><gtr:description>EMPIRIKAL Consortium</gtr:description><gtr:id>E4D99DF2-FD9C-4F3C-B22E-5724D208A75D</gtr:id><gtr:impact>First investigator meeting held October 2012. Protocol modifications.</gtr:impact><gtr:outcomeId>dvHNwbVBuxo-2</gtr:outcomeId><gtr:partnerContribution>Planning of the protocol. Potential patient involvement.</gtr:partnerContribution><gtr:piContribution>We have provided the underpinning science to the clinical trial (EMPIRIKAL) of a novel membrane associated complement regulator, have formulated the clinical protocol and have secured funding with the MRC DCS to enable the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital NHS Foundation Trust (NCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Empirikal Patient Recruiting Centres</gtr:description><gtr:id>582CD199-320F-4149-8487-C92322D35D3D</gtr:id><gtr:impact>recruitment to Cohort 1 of the study completed (n=80).</gtr:impact><gtr:outcomeId>jDPDP6NXrx5-8</gtr:outcomeId><gtr:partnerContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:partnerContribution><gtr:piContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>WellChild Laboratory</gtr:department><gtr:description>Well Child Clinic Professor Neil Dalton</gtr:description><gtr:id>27ED8891-B638-40F6-B8CC-D760F53293B5</gtr:id><gtr:impact>Samples analysis programe in place</gtr:impact><gtr:outcomeId>aJj1NeXsxb5-1</gtr:outcomeId><gtr:partnerContribution>Will complete the analysis of participant research samples</gtr:partnerContribution><gtr:piContribution>Will complete the analysis of participant research samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Empirikal Patient Recruiting Centres</gtr:description><gtr:id>C4BE91C5-FDCD-453F-B7FE-2000FC3C2586</gtr:id><gtr:impact>recruitment to Cohort 1 of the study completed (n=80).</gtr:impact><gtr:outcomeId>jDPDP6NXrx5-3</gtr:outcomeId><gtr:partnerContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:partnerContribution><gtr:piContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Empirikal Patient Recruiting Centres</gtr:description><gtr:id>D0664127-73A7-42E0-87CB-682643E9FC1D</gtr:id><gtr:impact>recruitment to Cohort 1 of the study completed (n=80).</gtr:impact><gtr:outcomeId>jDPDP6NXrx5-10</gtr:outcomeId><gtr:partnerContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:partnerContribution><gtr:piContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Protein Therapeutics Laboratory</gtr:department><gtr:description>Protein Therapeutics Laboratory</gtr:description><gtr:id>2DB3AE60-B517-4172-8394-7D55EAF49FF5</gtr:id><gtr:impact>Samples analysis programme in place</gtr:impact><gtr:outcomeId>X8U5AhJKPYK-1</gtr:outcomeId><gtr:partnerContribution>Will complete the analysis of particpant research samples</gtr:partnerContribution><gtr:piContribution>Will complete the analysis of particpant research samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff and Vale University Health Board</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Empirikal Patient Recruiting Centres</gtr:description><gtr:id>729DC0B0-0E8D-4FF7-BC9A-C195B3EB6370</gtr:id><gtr:impact>recruitment to Cohort 1 of the study completed (n=80).</gtr:impact><gtr:outcomeId>jDPDP6NXrx5-5</gtr:outcomeId><gtr:partnerContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:partnerContribution><gtr:piContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free London NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Empirikal Patient Recruiting Centres</gtr:description><gtr:id>07E417E9-C0FD-42B6-A989-41C0E37CF623</gtr:id><gtr:impact>recruitment to Cohort 1 of the study completed (n=80).</gtr:impact><gtr:outcomeId>jDPDP6NXrx5-2</gtr:outcomeId><gtr:partnerContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:partnerContribution><gtr:piContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fujifilm</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Fujifilm Diosynth Biotechnologies</gtr:department><gtr:description>FujiFilm Diosynth Biotechnologies</gtr:description><gtr:id>FC9C05EC-A102-4329-8F8D-BF12ABF2174B</gtr:id><gtr:impact>Drug substance suitable for clinical trial formulation</gtr:impact><gtr:outcomeId>QGcQkm5V6PE-1</gtr:outcomeId><gtr:partnerContribution>Produced drug substance to cGMP with associated documentation and stability studies</gtr:partnerContribution><gtr:piContribution>drug Substance manufacture - Provided update to manufacturing process, regular check on manufacturing step and QA/QC. Developed new assay for drug product</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Empirikal Patient Recruiting Centres</gtr:description><gtr:id>71DF3E4F-3161-439E-A5CC-4BED79A11071</gtr:id><gtr:impact>recruitment to Cohort 1 of the study completed (n=80).</gtr:impact><gtr:outcomeId>jDPDP6NXrx5-1</gtr:outcomeId><gtr:partnerContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:partnerContribution><gtr:piContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Progeny Software inc</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Progeny</gtr:description><gtr:id>C1F3A9A0-1095-40EE-8063-543006AC4920</gtr:id><gtr:impact>Database in place</gtr:impact><gtr:outcomeId>fWJGVqssuQP-1</gtr:outcomeId><gtr:partnerContribution>Enusre human tissue act is abided</gtr:partnerContribution><gtr:piContribution>Provided the samples LIMS systems</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Addenbrooke's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DMEC (AB, KW, AC, ASF, DC, NT)</gtr:description><gtr:id>5B01E46D-A187-4081-9AF0-1CA3BC455859</gtr:id><gtr:impact>Committee in place</gtr:impact><gtr:outcomeId>hgWJHX2aPhY-5</gtr:outcomeId><gtr:partnerContribution>Review of unblinded data and give recommendation to TSC</gtr:partnerContribution><gtr:piContribution>Data Monitoring and Ethics Committee for the EMPIRIKAL Trial: Chair and members: independent clinicians, immunologists and statisticians.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>DMEC (AB, KW, AC, ASF, DC, NT)</gtr:description><gtr:id>2807DAC0-E1CF-4CAB-8AD9-61E367B646E0</gtr:id><gtr:impact>Committee in place</gtr:impact><gtr:outcomeId>hgWJHX2aPhY-3</gtr:outcomeId><gtr:partnerContribution>Review of unblinded data and give recommendation to TSC</gtr:partnerContribution><gtr:piContribution>Data Monitoring and Ethics Committee for the EMPIRIKAL Trial: Chair and members: independent clinicians, immunologists and statisticians.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Veterinary School</gtr:department><gtr:description>Mirococept collaboration with Cambridge University</gtr:description><gtr:id>1F2D8B97-F5C5-4F19-97B6-99C0D35A37FF</gtr:id><gtr:impact>Supportive data for clinical use of Mirococept in novel indications.</gtr:impact><gtr:outcomeId>F66QxKTQ74L-1</gtr:outcomeId><gtr:partnerContribution>Providing laboratory facilities and Factor I</gtr:partnerContribution><gtr:piContribution>Supplied Mirococept and other reagents and collaborated in experiments.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sealed Envelope</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Randomisation System</gtr:description><gtr:id>6839FC86-E5E5-41D4-A2BE-CDEC2FA7AD55</gtr:id><gtr:impact>Randomisation data base in place</gtr:impact><gtr:outcomeId>Kx4cLt6Zoiy-1</gtr:outcomeId><gtr:partnerContribution>Randomisation data base</gtr:partnerContribution><gtr:piContribution>produced randomisation kit numbers accordinly to the projet stratification factors</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DMEC (AB, KW, AC, ASF, DC, NT)</gtr:description><gtr:id>657577BB-F08E-4547-BDD5-9FC3A1891816</gtr:id><gtr:impact>Committee in place</gtr:impact><gtr:outcomeId>hgWJHX2aPhY-1</gtr:outcomeId><gtr:partnerContribution>Review of unblinded data and give recommendation to TSC</gtr:partnerContribution><gtr:piContribution>Data Monitoring and Ethics Committee for the EMPIRIKAL Trial: Chair and members: independent clinicians, immunologists and statisticians.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Comark Instruments</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Comark Instruments</gtr:description><gtr:id>79366AC1-42BA-4FD3-9DF2-368BBE0F91D3</gtr:id><gtr:impact>System in place</gtr:impact><gtr:outcomeId>qFYM6HVCDb1-1</gtr:outcomeId><gtr:partnerContribution>Ensure the cold storage condition of the drug are maintained</gtr:partnerContribution><gtr:piContribution>Freezer temperature monitoirng system</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aesica Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Vialling Company Aesica</gtr:description><gtr:id>05C0F4A6-CF2E-4B8D-A5FE-7EC77403120B</gtr:id><gtr:impact>Drug Product suitable for clinical trials</gtr:impact><gtr:outcomeId>s2fLobxaKuo-1</gtr:outcomeId><gtr:partnerContribution>Producedand stored vialled drug product as frozen solution fomulation performed sterility tests etc</gtr:partnerContribution><gtr:piContribution>Drug product manufacture - Supply of drug specification and previous stability data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Barts Health NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Empirikal Patient Recruiting Centres</gtr:description><gtr:id>E995FC1A-6C41-43BE-9D15-6E51BEE4D209</gtr:id><gtr:impact>recruitment to Cohort 1 of the study completed (n=80).</gtr:impact><gtr:outcomeId>jDPDP6NXrx5-7</gtr:outcomeId><gtr:partnerContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:partnerContribution><gtr:piContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Transplant Centre</gtr:department><gtr:description>Trial Steering Committee</gtr:description><gtr:id>97672FF0-9EC8-43D1-9AF0-36795C54E642</gtr:id><gtr:impact>Committee in place</gtr:impact><gtr:outcomeId>KRQJ4miv4HV-1</gtr:outcomeId><gtr:partnerContribution>Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists</gtr:partnerContribution><gtr:piContribution>Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Liver Sciences</gtr:department><gtr:description>DMEC (AB, KW, AC, ASF, DC, NT)</gtr:description><gtr:id>3A0667F0-3317-4760-9BB6-8C9C5E190144</gtr:id><gtr:impact>Committee in place</gtr:impact><gtr:outcomeId>hgWJHX2aPhY-4</gtr:outcomeId><gtr:partnerContribution>Review of unblinded data and give recommendation to TSC</gtr:partnerContribution><gtr:piContribution>Data Monitoring and Ethics Committee for the EMPIRIKAL Trial: Chair and members: independent clinicians, immunologists and statisticians.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hammersmith Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Empirikal Patient Recruiting Centres</gtr:description><gtr:id>89C5E9AA-50FE-4917-AE62-2A18637F253F</gtr:id><gtr:impact>recruitment to Cohort 1 of the study completed (n=80).</gtr:impact><gtr:outcomeId>jDPDP6NXrx5-4</gtr:outcomeId><gtr:partnerContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:partnerContribution><gtr:piContribution>recruitment to Cohort 1 of the study completed (n=80).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Steve Sacks - Royal Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F8E4B50C-F421-4A6C-AF8E-60D5AFADD806</gtr:id><gtr:impact>Invited speaker, Royal Society Meeting on Complement: driver of inflammation and therapeutic target in diverse disease, Buckinghamshire, UK</gtr:impact><gtr:outcomeId>56d815e68eab89.13903213</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - 8th International Conference on Complement Therapeutics, Crete, Greece</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BBDA140A-E3E8-4BC8-ADC4-7FAAC23AB280</gtr:id><gtr:impact>Invited speaker</gtr:impact><gtr:outcomeId>56d8175fc9a761.29910487</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminar - Sir William Dunn School of Pathology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6BA5BB01-0EB8-4642-8CD2-F83A00F15BA9</gtr:id><gtr:impact>Interest and further discussions followed

Strengthened links in support of application for UKRMP Immunology Stem Cell Hub</gtr:impact><gtr:outcomeId>545b88d8231e42.40563279</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - Complement UK Symposium and Training Course, Cambridge, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DB8E8A17-BD62-4EE2-A1F9-D3C3ACBB67A1</gtr:id><gtr:impact>Co-organiser and speaker</gtr:impact><gtr:outcomeId>56d816d04fcd73.91382365</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International conferenc on complement therapeutics Rhodes 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>655F7E04-563D-4582-B906-CB086EF94BFF</gtr:id><gtr:impact>Invited speaker at the 9th International conference on complement therapeutics, Rhodes 2016. Talk give on the Role of Collectin 11 in injury of the newly transplanted kidney providing opportunity for feedback and discussion</gtr:impact><gtr:outcomeId>58c90ef181cf92.70179679</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - CEOT Symposium, Phoenix, USA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>30AC07CD-71B3-4451-A9E9-699F594F9E0E</gtr:id><gtr:impact>Invited speaker</gtr:impact><gtr:outcomeId>56d8184e324847.78787772</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - BANFF-CST</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>474EFBE4-C997-4666-A76F-F97BBD78C42E</gtr:id><gtr:impact>Invited speaker for the BANFF-CST Joint Scientific Meeting, Vancouver, Canada</gtr:impact><gtr:outcomeId>56d8179b540a18.88129981</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speaker at BTS Glasgow conference, 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D34F7C24-5A73-484A-8279-E1582BBC1F1F</gtr:id><gtr:impact>Presented Reseach to academic audience at the 2016 British Transplantation Society conference in Glasgow</gtr:impact><gtr:outcomeId>56d81466e70412.16586695</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Session Organiser for BSI 2013</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AE94631A-BB41-4A77-A79F-F0C37CAB5F24</gtr:id><gtr:impact>None as yet - Meeting occurring 2-5 December 2013</gtr:impact><gtr:outcomeId>Bi5LqS5quVC</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.bsicongress.com/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EMPIRIKAL investigator meeting BTS Harrogate 2017</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F3C27B23-B735-4851-AC2B-69464AD4EC7E</gtr:id><gtr:impact>Presented baseline data and characteristics of Cohort 1 to other PI and Investigators. Generated discussion and questions between Investigators and will hopefully lead to other centres taking part in the next Cohort.</gtr:impact><gtr:outcomeId>58c918d7edec19.01069726</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - American Society of Nephrology, San Diego, USA</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8C0186FF-5AF3-41EE-8F16-25F2F3F87407</gtr:id><gtr:impact>Invited speaker</gtr:impact><gtr:outcomeId>56d817d24d4f97.95177549</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - Joint British Transplantation Society and Nederlandse Tranplantatie Vereniging Congress, Bournemouth, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6CC3E9A3-AC63-4FD8-8A09-17253D992890</gtr:id><gtr:impact>Invited speaker. 
Talk title: ' A new signal for cell death in post-ischaemic injury'</gtr:impact><gtr:outcomeId>56d8167e586763.03326367</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary- The Science and Art of Transplantation</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>73DD28DE-0D2A-4D1F-AF83-07369873D93E</gtr:id><gtr:impact>The exhibition, attended by 189 visitors throughout the day, consisted of five multimedia galleries, with volunteers from the Centre on hand throughout the day to speak to visitors about their research. ? Pioneers Gallery - interviews from pioneers of science and transplantation, connecting MRC discoveries with the treatment of transplant patients today
? Extending the life of the transplant; &amp;quot;Pepper's Ghost&amp;quot; holographic model with kidney perfusion video footage 
? A life without medication; multi-player video game 
? Cell Transplantation; plasma information screen focusing on the hepatocyte programme, islet, and bone marrow work 
? Patient journey; patient wall with stories from 28 transplant recipients and their families. Patients Richard Lane and Lesley Beadle also attended giving visitors the opportunity to hear first-hand about life as a transplant donor or recipient

84 % of those who returned a feedback form reported that the exhibition had improved their understanding of the Medical Research Council and of the work that it has achieved. Further, 81% claimed a better understanding of organ transplantation following the event.
? &amp;quot;Excellent exhibition. Great use of multimedia and very worthwhile exhibit. A very good way to commemorate the MRC!&amp;quot;
? &amp;quot;It was great! And no jargon so easily understandable&amp;quot;
? &amp;quot;Really enjoyed the exhibition and speaking with the researchers especially. The work they are doing is so interesting!&amp;quot;
? &amp;quot;Keep up the good work!&amp;quot;
? &amp;quot;I appreciated how well the professor explained the research and how encouraging they were&amp;quot;
? &amp;quot;Really enjoyed layout and presentation of projected images. Great interactive game!&amp;quot;

See text above for statistics and feedback. We have been asked to re-use some of our exhibits (the digital multiplayer interactive game showing transplant tolerance versus rejection) for the Science Museum late series for the MRC Max Perutz Science Writing Award ceremony.</gtr:impact><gtr:outcomeId>E4MtCpaDzmU</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://transplantation.kcl.ac.uk/sections/site/education-information</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>clinical trials day 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>26CF387D-F6EF-452E-8B2E-2E60F5D8BBF8</gtr:id><gtr:impact>Leaflet and attendance at clinical trials day organised by the GSTT NHS trust in hospital foyer - describing trials based within the centre - stall open to general public.</gtr:impact><gtr:outcomeId>58c6c291dd0e95.58614322</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Translational award</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>098300/Z/12/Z</gtr:fundingRef><gtr:id>A88FA764-69FF-4780-8F89-CCF2C674AA7A</gtr:id><gtr:outcomeId>D8wgDDftFcb</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>32500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KCL funding</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>DE09705E-15D0-443E-8EE9-D84BB6266626</gtr:id><gtr:outcomeId>58c915d2c8e943.16888684</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The right to use Mirococept in a specific perfusion formulation for use in kidneys prior to transplantation is protected by a patent. The finding that Mirococept can provide protection to organs immediately following</gtr:description><gtr:grantRef>G1001197</gtr:grantRef><gtr:id>08AD108A-3619-44D3-9C21-16D91F9F0CF7</gtr:id><gtr:impact>Mirococept is being explored for several other indications</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>juEc4HPtTRK</gtr:outcomeId><gtr:patentId>WO2011027175</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Mirococept in renal transplantation</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Recovery of IP and materials related to membrane-localising (&amp;quot;cytotopic&amp;quot;) technology discovered by our lead protein chemist and head of Protein Therapeutics Laboratory (before joining our Centre).</gtr:description><gtr:grantRef>G1001197</gtr:grantRef><gtr:id>B30E1A14-8586-4F08-83F3-684861DFC11F</gtr:id><gtr:impact>Return of the IP will enable new grant proposals and the conduct of a Phase IIB efficacy study in transplant patients.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>7F30F5F7194</gtr:outcomeId><gtr:patentId>US7888318</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Anticomplement Compounds</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>It has been found that linkage of anticoagulant peptides to membrane-localising (&amp;quot;cytotopic&amp;quot;) reagents generates conjugates which are capable of inhibiting thrombin when attached to cell surfaces. This enables organs to be anticoagulated by perfusion ex-vivo prior to transplantation into the recipient. For the first time, it appears to be possible to separate local antithrombotic effects from systemic pharmacological ones using a readily translatable therapeutic agent.</gtr:description><gtr:grantRef>G1001197</gtr:grantRef><gtr:id>8B5BB98D-DAA3-4845-8578-D71C1ABABC56</gtr:id><gtr:impact>It may be possible to control thrombosis in transplantation (for example, in pancreatic and islet cell transplantation and in the prevention of antibody-mediated acute rejection) using this approach, as shown in early pre-clinical models in rat.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>7CE388A2547</gtr:outcomeId><gtr:patentId>WO2011027175</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Antithrombotic Compounds</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Technology Strategy Board Assessor Briefing for Healthcare</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C93E5C05-9889-47FB-A658-0019A145E66B</gtr:id><gtr:outcomeId>545ca1618df9e3.81311432</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Membrane - interactive complement inhibitor used by ex vivo perfusion into isolated organ. About to enter definitive Phase II study. Drug manufacture completed to accepted standard. MHRA approved. Patient recruitment imminent. Souce of funding: MRC DCS grant. Recruitment began in July 2015 and 19 patients are now undergoing treatment.</gtr:description><gtr:id>ECDD985B-5251-469C-B589-AE8CA79C8C2F</gtr:id><gtr:impact>Validation of the membrane-binding (cytotopic) approach used in Mirococept and the consequent development of this technology as a platform. Large scale manufacture and quality assessment for clinical trial completed. Completed investigators brochure. Ethics approved. MHRA approved. Patient recruitment open.</gtr:impact><gtr:outcomeId>tFCqbjC6TeG</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Empirikal-Mirococept</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.mykidney.org/Research/ResearchAtGuys.aspx</gtr:url><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Complement inhibitor</gtr:description><gtr:id>E5E7FB78-E8F5-493C-B9CA-350BEE1C1F92</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>WpTXfAs1Cy1</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mirococept</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Precursor reagent for Mirococept manufacture</gtr:description><gtr:id>38029A1C-9974-42B5-9AC2-6EC5248CE20E</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>WkuWeuS4nwU</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>APT542</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Complement inhibitor, precursor to Mirococept</gtr:description><gtr:id>1F1533F4-0F46-4ADA-9491-9B7D024EACB3</gtr:id><gtr:impact>Demonstration of cofactor activity towards complement Factor I in this fragment of CR1</gtr:impact><gtr:outcomeId>hzCK8gtYprE</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>APT154</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C7E8498E-B45E-41D5-B2C8-ED29344CB33A</gtr:id><gtr:title>The role of complement in the early immune response to transplantation.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff9ec214617661fdfb7e5229c6dcdcbf"><gtr:id>ff9ec214617661fdfb7e5229c6dcdcbf</gtr:id><gtr:otherNames>Sacks SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>pm_13110_20_22627861</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4BC55E6-2916-41D3-BE46-F45A1B3BC589</gtr:id><gtr:title>Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient</gtr:title><gtr:parentPublicationTitle>Transplantation Reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/722c4ac63ded662dc422a0a61495e934"><gtr:id>722c4ac63ded662dc422a0a61495e934</gtr:id><gtr:otherNames>Manook M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5aa9340a0e6a96.56336059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CA57A38-071A-4031-AE4B-5E5F618C84E7</gtr:id><gtr:title>Control of innate immunological mechanisms as a route to drug minimization.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a316adfc796e81a38c1044af9c04fdd4"><gtr:id>a316adfc796e81a38c1044af9c04fdd4</gtr:id><gtr:otherNames>Asgari E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn><gtr:outcomeId>561527ebe8cd32.07369574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>557F5B6A-838B-4B8C-A327-8DC9383A9FD2</gtr:id><gtr:title>Mechanisms of rejection: role of complement.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f41571013db636d13570fa10eaf335ba"><gtr:id>f41571013db636d13570fa10eaf335ba</gtr:id><gtr:otherNames>Farrar CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn><gtr:outcomeId>561527ec2ee202.03635500</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>866E9FA3-7EB7-4FDF-AF9D-B443D9A3C31C</gtr:id><gtr:title>The innate immune system and transplantation.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor perspectives in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f41571013db636d13570fa10eaf335ba"><gtr:id>f41571013db636d13570fa10eaf335ba</gtr:id><gtr:otherNames>Farrar CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2157-1422</gtr:issn><gtr:outcomeId>pm_13110_20_24086066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3B99DB0-D219-4EC8-A2B5-FA4A24A39A54</gtr:id><gtr:title>Complement Recognition Pathways in Renal Transplantation.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8c0c8e4bc3c81039bafb922af1e3d42"><gtr:id>a8c0c8e4bc3c81039bafb922af1e3d42</gtr:id><gtr:otherNames>Nauser CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5a35e2be03cc79.48665408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86DF9EAD-BBED-4073-8FA1-E35DDDDFE22C</gtr:id><gtr:title>A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c68d807cc18b764a10aa4b0584215bb"><gtr:id>1c68d807cc18b764a10aa4b0584215bb</gtr:id><gtr:otherNames>Kassimatis T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5aa9328ec52a18.43677100</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001197</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>046212FE-8853-46F0-B1E7-3CBA4770A15F</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.4  Surgery</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>